AIMS: Androgen-deprivation therapy (ADT) is a main treatment option for patients with prostate cancer (PCa), but its effect on cognition remains unclear.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
The primary purpose of this cross-sectional case-control study was to evaluate the effects of ADT on cognition in Chinese PCa patients.
METHODS: Participants included PCa patients who had undergone ADT (ADT group, n = 33) and patients who did not undergo ADT (non-ADT group, n = 32), as well as age- and education-matched healthy controls (HC group, n = 35). All participants were examined using the neuropsychological battery aimed at assessing several cognitive domains including attention, memory and information processing performance.
RESULTS: The ADT group obtained significantly worse scores than the non-ADT and HC groups in the following neuropsychological tests: Recognition (P < 0.01), WAIS Digit Span forward (P < 0.05), Trailmaking B (P < 0.01) and Stroop Interference test (P < 0.01). No significant difference was found between the non-ADT and HC groups (P > 0.05).
CONCLUSIONS: Chinese PCa patients receiving ADT showed cognitive impairments in several domains including memory, attention and information processing performance.
Yang J, Zhong F, Qiu J, Wang K. Are you the author?
Department of Neurology, The Affiliated Anhui Provincial Hospital, Anhui Medical University, Hefei, China.
Reference: Asia Pac J Clin Oncol. 2015 Apr 9. Epub ahead of print.